<DOC>
	<DOCNO>NCT01158235</DOCNO>
	<brief_summary>This pilot study conduct evaluate safety , local tolerability efficacy LTX-109 ( Lytixar™ ) , lytic peptide design kill bacterias quickly efficient . LTX-109 ( Lytixar™ ) apply anterior naris subject carrier nasal colony MRSA/MSSA . The extent systemic absorption LTX -109 apply anterior naris evaluate effect Lytixar™ clear colony MRSA/MSSA observation period Week 2 Week 9 treatment .</brief_summary>
	<brief_title>A Phase I/IIa Study Evaluate Safety , Tolerability Efficacy Topical LTX-109 Subjects Nasally Colonized With Methicillin-resistant/-Sensitive Staphylococcus Aureus ( MRSA/MSSA )</brief_title>
	<detailed_description>Subjects persistent colony MRSA/MSSA nostril recruit receive either active treatment placebo . This dose escalating study . First grout receive either 1 % Lytixar™ placebo , next group 2 % Lytixar™ placebo finally 5 % Lytixar™ placebo . Dose escalation perform brief safety evaluation tolerability application Lytixar™/placebo vehicle TID three day . Pharmacokinetic sample collect subject willing . Subjects follow 9 week initiation treatment .</detailed_description>
	<mesh_term>Methicillin</mesh_term>
	<criteria>Male female subject age 16 75 , inclusive . Female subject must nonpregnant , nonlactating . Female subject child bear potential male subject female partner childbearing potential must use adequate form diaphragm condom spermicidal prior entry study two week follow completion followup procedures 9 week treatment . Hormone contraception hormonal IUDs alone acceptable contraception Signed date write informed consent subject . Subject 's medical condition stable , clinically significant abnormality . Subject 's prestudy laboratory screen haematology , clinical chemistry urinalysis normal abnormal , consider clinically significant . Subjects must able understand subject information consent form , willing return study site follow visit , comply requirement , instruction restriction study list informed consent form . All family member , subject carry MRSA ( applicable MSSA positive ) also screen MRSA . Subjects eligible may include study , family member eligible willing participate offer treatment decolonization MRSA accord standard treatment investigator choice . Negative nasal culture MRSA/MSSA first screen visit . Negative nasal culture MRSA/MSSA occasion runin period day 14 3 day prior Baseline . Severe eczema ( eczema infect MRSA ) skin wound , clinically significant accord investigator . Previous concurrent treatment antimicrobial infection within last 28 day prior baseline . MRSA decolonization attempt previous 6 month ( prior treatment MRSA infection exclusion criterion ) . Systolic BP ≥170 mmHg , diastolic BP ≥100 mmHg HR ≥110 bpm . Inability take medication nasally . Evidence active rhinitis , sinusitis , upper respiratory infection . Disease region application site , significant history trauma skin disease region application site , current nasal skin nasal septum condition require treatment nasal surgery previous 3 month . Significant ongoing history drug alcohol abuse opinion investigator make subject unsuitable enrolment . Use prescription non prescription drug within minimum 7 day prior first dose study medication . Subjects stable dos nonprescription painkiller , antiinflammatory drug ( paracetamol NSAIDs ) , oral antidiabetic insulin may allow include study discretion investigator . Known allergic reaction hypersensitivity significant severity general specifically component study medication . Systemic illness require treatment within 28 day prior baseline . Clinically significant illness ( defined investigator ) past 4 week Screening visit . Current history significant hepatic , renal , endocrine , cardiac , nervous , psychiatric , gastrointestinal , pulmonary , haematological , metabolic disorder stable condition . Malignancy &lt; 5 year since final treatment . Current history significant disease condition know interfere absorption , distribution , metabolism excretion drug . Known positive test Human Immunodeficiency Virus ( HIV ) antibody , hepatitis B virus surface antigen hepatitis C virus antibody . Other unspecified reason , opinion investigator make subject unsuitable enrolment . Treatment investigational drug within 30 day prior first dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>MRSA</keyword>
	<keyword>nose</keyword>
</DOC>